Table 5.

Distribution of “high” and “low” expresser of ER, PR, HER2, and KRT5/17 between dasatinib-responder and nonresponder breast tumor groups predicted by the six-gene predictor

GeneExpression level *Predicted nonresponder (80)Predicted responder (54)χ2 test (P)
HER2H46210.035
L3433
ERH47200.014
L3334
PRH45220.078
L3532
KRT 5/17H28310.010
L5223
  • * The median expression level of a gene across the 134 tumors was used to define “high” (H) or “low” (L) expression. A tumor was designated as “L” if its expression was below the median level and designated as “H” if its expression was above the median.